Published • loading... • Updated
$125m financing to see Macclesfield’s Redx list on Nasdaq
Summary by BusinessCloud.co.uk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
$125m financing to see Macclesfield’s Redx list on Nasdaq
Redx Pharma, a drug discovery and development company, has sealed a long-term funding deal that will see it list on the US-based Nasdaq exchange as Fibrx Therapeutics. Based in Macclesfield, Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease. The news follows the announcement that Redx and Sky Bioscience Inc have agreed a ‘transaction agreem…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
